Safety, Tolerability and Efficacy of Repeated Intravenous Infusions of KHK4083, a Fully Human Anti-OX40 Monoclonal Antibody, in Japanese Patients with Moderate to Severe

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting both adults and children with worldwide prevalence rates of up to 20% [1 –3]. Of these, one-third of adults are affected with moderate to severe disease [4,5]. The standard care for skin inflammation in Japan includes topical treatments such as topical corticosteroids or tacrolimus ointment [6]. While oral therapy including cyclosporine and systemic corticosteroids can be effective in cases of AD refractory to topical treatments, systemic side effects are commonly observed in long-term use [6,7].

Source: Journal of Dermatological Science - June 11, 2020 Category: Dermatology Authors: H. Nakagawa, H. Iizuka, O. Nemoto, M. Shimabe, Y. Furukawa, N. Kikuta, K. Ootaki Source Type: research